Feasibility of treatment-free remission with generic imatinib
Deepak Goni(Post Graduate Institute of Medical Education and Research), Pankaj Malhotra(Post Graduate Institute of Medical Education and Research), Deepesh Lad(Post Graduate Institute of Medical Education and Research), Nishant Jindal(Post Graduate Institute of Medical Education and Research), Aditya Jandial(Post Graduate Institute of Medical Education and Research), Ram Vasudevan Nampoothiri(Post Graduate Institute of Medical Education and Research), Neelam Varma(Nagpur Institute of Technology), Gaurav Prakash(Post Graduate Institute of Medical Education and Research), Charanpreet Singh(Post Graduate Institute of Medical Education and Research), Arihant Jain(California University of Pennsylvania), Shano Naseem(Post Graduate Institute of Medical Education and Research), Alka Khadwal(Post Graduate Institute of Medical Education and Research)
Cited by 14
Related Papers
Global Burden of Multiple Myeloma
|JAMA Oncology|2018|631
X-Linked Dyskeratosis Congenita Is Predominantly Caused by Missense Mutations in the DKC1 Gene
|The American Journal of Human Genetics|1999|264
Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis – Case report and systematic review
|Journal of Infection|2008|114
Imatinib has adverse effect on growth in children with chronic myeloid leukemia
|Pediatric Blood & Cancer|2011|95
Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF‐1 axis
|Pediatric Blood & Cancer|2013|85